Status:
UNKNOWN
The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment
Lead Sponsor:
The First Affiliated Hospital of Dalian Medical University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
Brief Summary
The study evaluates artificial intelligence method based on multimodal magnetic resonance imaging (MRI) images and clinical data in preoperative prediction of prognosis in early hepatocellular carcino...
Detailed Description
The prognosis prediction of early stage hepatocellular carcinoma (HCC) after minimally invasive treatment involves clinical decision of treatment and follow-up. Magnetic resonance imaging (MRI) has be...
Eligibility Criteria
Inclusion
- Hepatocellular carcinoma patients received minimally invasive treatment (transcatheter arterial chemoembolization, radiofrequency ablation, or combined) or hepatectomy;
- Patients received MRI examination within 1 month before treatment;
- Complete post-treatment prognosis information.
Exclusion
- local or systemic treatment before MR examination;
- Incomplete clinical and pathological data;
- Heavy image artifacts.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04299919
Start Date
April 1 2007
End Date
June 30 2024
Last Update
March 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China, 116000